#1 Clinical Trials Search in Europe

Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8

This article discusses a clinical trial investigating the use of Eltrekibart, a new drug containing a humanized IgG4 kappa monoclonal antibody, for the treatment of moderate to severe hidradenitis suppurativa (HS). The study aims to assess the safety and efficacy of Eltrekibart in adult patients with this challenging skin condition. We’ll explore the trial’s objectives, eligibility criteria, and potential benefits for those suffering from HS.

Table of Contents

What is Eltrekibart?

Eltrekibart is a new medication being studied for the treatment of moderate to severe hidradenitis suppurativa (HS). It is classified as a humanised IgG4 kappa monoclonal antibody that targets specific proteins in the body called chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8).[1]

This medication is currently in the experimental stage and is being tested in clinical trials. It is not yet approved for general use and is considered an investigational medicinal product.[1]

Target Condition: Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic skin condition that causes painful, swollen bumps to form in areas where skin rubs together, such as the armpits, groin, and under the breasts. These bumps can become infected and form tunnels under the skin, leading to scarring.[1]

HS can be classified into different stages of severity, known as Hurley Stages. The clinical trial for Eltrekibart focuses on patients with moderate to severe HS, which typically includes those with Hurley Stage II or III.[1]

How Eltrekibart Works

Eltrekibart is designed to work by targeting specific proteins in the body called chemokines. These chemokines are involved in inflammation and immune responses. By blocking these proteins, Eltrekibart aims to reduce inflammation and potentially improve the symptoms of hidradenitis suppurativa.[1]

The medication is administered as a solution for infusion, which means it is given directly into the bloodstream through a vein. However, the clinical trial is testing it as a subcutaneous injection, which is an injection given just under the skin.[1]

Clinical Trial Details

The clinical trial for Eltrekibart is a Phase 2b study, which means it is testing the effectiveness and safety of the drug in a larger group of people with hidradenitis suppurativa. The study is described as double-blind and placebo-controlled, which are important features to ensure the reliability of the results.[1]

The main goal of the trial is to determine if Eltrekibart is better than a placebo in achieving what’s called a Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) in adults with moderate-to-severe HS. This response is measured at week 16 of the treatment.[1]

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some of the key inclusion criteria are:

  • Have had a diagnosis of HS for at least 12 months
  • Have HS lesions in at least 2 distinct body areas, with at least one lesion being Hurley Stage II or III
  • Have at least 5 abscesses and inflammatory nodules
  • Agree to use topical antiseptics daily
  • Have had an inadequate response or intolerance to a 28-day course of oral antibiotics

Some reasons why a person might not be eligible for the trial include:

  • Having more than 20 draining fistulae
  • Recent surgical treatment for HS
  • Having other active skin conditions that could interfere with HS assessment
  • Current or recent infections
  • Being immunocompromised
  • History of substance abuse within the past year

These criteria help ensure the safety of participants and the accuracy of the study results.[1]

Potential Benefits

While it’s important to note that Eltrekibart is still in the testing phase and its effectiveness is not yet proven, the hope is that it could provide a new treatment option for people with moderate to severe hidradenitis suppurativa who haven’t responded well to other treatments.[1]

If successful, Eltrekibart could potentially help reduce inflammation, decrease the number of painful lesions, and improve the quality of life for people living with this challenging skin condition. However, more research is needed to confirm these potential benefits and ensure the safety of the medication.[1]

Aspect Details
Drug Name Eltrekibart
Active Substance Humanised IgG4 kappa monoclonal antibody against CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8
Condition Treated Moderate to Severe Hidradenitis Suppurativa
Trial Phase Phase 2b
Administration Method Subcutaneous Injection
Primary Endpoint Percentage of participants achieving HiSCR50 at Week 16
Key Inclusion Criteria HS diagnosis for ≥12 months, lesions in ≥2 anatomical regions, inadequate response to oral antibiotics
Key Exclusion Criteria >20 draining fistulae, recent HS surgery, active infections, immunocompromised status

FAQ

  • What is Eltrekibart? Eltrekibart is an investigational drug containing a humanized IgG4 kappa monoclonal antibody that targets specific proteins (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8) involved in inflammation. It is being studied as a potential treatment for moderate to severe hidradenitis suppurativa.
  • What is the main goal of this clinical trial? The main objective of this trial is to determine if Eltrekibart is more effective than a placebo in achieving a Hidradenitis Suppurativa Clinical Response (HiSCR50) in adult patients with moderate to severe hidradenitis suppurativa.
  • Who can participate in this clinical trial? Participants must be adults diagnosed with moderate to severe hidradenitis suppurativa for at least 12 months, have lesions in at least 2 distinct anatomical regions, and have had an inadequate response or intolerance to a 28-day course of oral antibiotics, among other criteria.
  • How is Eltrekibart administered? Eltrekibart is administered through subcutaneous injection, which means it is injected under the skin.
  • What is the duration of the treatment in this trial? The primary endpoint of the study is measured at Week 16, but the maximum treatment period mentioned in the trial information is 50 weeks.

Ongoing Clinical Trials on Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8

  • Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated drugs:
    Belgium Croatia Czechia Denmark France Germany +8

  • Study of Eltrekibart for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Germany Greece Poland

Glossary

  • Hidradenitis Suppurativa (HS): A chronic skin condition characterized by painful, inflamed lesions typically in areas where skin rubs together, such as the armpits, groin, and under the breasts.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In this case, it targets specific inflammation-related proteins.
  • Placebo: A substance that has no active ingredients and is used as a control in clinical trials to test the effectiveness of a drug.
  • HiSCR50: Hidradenitis Suppurativa Clinical Response 50, a measure used to assess the effectiveness of treatments for HS. It typically indicates a 50% reduction in inflammatory lesions.
  • Phase 2b Trial: A stage of clinical research that further evaluates the safety and efficacy of a drug, often testing different dosages.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and the muscle.
  • Hurley Stage: A classification system used to describe the severity of hidradenitis suppurativa, with stages ranging from I (mild) to III (severe).

References

  1. http://clinicaltrials.eu/trial/study-of-eltrekibart-for-adults-with-moderate-to-severe-hidradenitis-suppurativa/